Diabetes and obesity products like Ozempic/Wegovy and Mounjaro are gaining share at the expense of metformin and SGLT-2 inhibitors. Scrip looks at data on prescription shifts in the US while examining if metformin remains attractive and whether a recent study showing efficacy in long COVID treatment could help

As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.

Most CEOs/MDs at leading listed foreign and domestic drug firms in India took home bigger pay packages in 2021-22, a period that also saw several top-level exits including at Abbott, Pfizer and Sanofi. Scrip examines some of the wider trends around executive compensation.

More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.